RET and neuroendocrine neoplasm: The most prevalent activating mutation was RET M918T (n = 7), which apart from MTC was also reported across a spectrum of additional neuroendocrine tumors, including paraganglioma, pheochromocytoma, and carcinoid tumors [47].